<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-06-08">June 8, 2017.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jan</forename><forename type="middle">L</forename><surname>Bro</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jean</forename><surname>Bousquet</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">the Division of Clinical Immunology and Allergy</orgName>
								<orgName type="institution">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Montpellier</settlement>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">Transylvania University</orgName>
								<address>
									<settlement>Brasov</settlement>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">University of Toronto</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Ioana</forename><surname>Agache</surname></persName>
						</author>
						<author>
							<persName><roleName>BHSc</roleName><forename type="first">Arnav</forename><surname>Agarwal</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Claus</forename><surname>Bachert</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Division of Allergy and Immunology</orgName>
								<orgName type="laboratory">the Upper Air-ways Research Laboratory</orgName>
								<orgName type="institution" key="instit1">Ghent University Hospital; g the Woolcock Institute</orgName>
								<orgName type="institution" key="instit2">Uni-versity of Sydney; h the Asthma &amp; Allergy Clinic</orgName>
								<orgName type="institution" key="instit3">Humanitas University</orgName>
								<address>
									<settlement>Rozzano</settlement>
									<region>Milan</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Public Health and Primary Care</orgName>
								<orgName type="institution">University of South Florida</orgName>
								<address>
									<settlement>Tampa</settlement>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">School of Health Sciences</orgName>
								<orgName type="institution">Leiden University Medical Center; k the Life and Health Sciences Research Institute (ICVS)</orgName>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department">ICVS/3B&apos;s-PT Government Associate Laboratory</orgName>
								<orgName type="institution">University of Minho</orgName>
								<address>
									<settlement>Braga, Braga/Guimarães</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sinthia</forename><surname>Bosnic-Anticevich</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><surname>Bpharm</surname></persName>
						</author>
						<author>
							<persName><roleName>DDS, MSc</roleName><forename type="first">Romina</forename><surname>Brignardello-Petersen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">G</forename><forename type="middle">Walter</forename><surname>Canonica</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Thomas</forename><surname>Casale</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Niels</forename><forename type="middle">H</forename><surname>Chavannes</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jaime</forename><surname>Correia De Sousa</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Alvaro</forename><forename type="middle">A</forename><surname>Cruz</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">ProAR-Center of Excellence for Asthma</orgName>
								<orgName type="institution">Federal University of Ba-hia</orgName>
								<address>
									<settlement>Salvador</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Carlos</forename><forename type="middle">A</forename><surname>Cuello-Garcia</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Pascal</forename><surname>Demoly</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">University Hospital of Montpellier</orgName>
								<address>
									<addrLine>and Sorbonne Uni-versit es</addrLine>
									<settlement>Montpellier</settlement>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="laboratory">UMR-S 1136</orgName>
								<orgName type="institution">UPMC</orgName>
								<address>
									<addrLine>Paris 06</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Equipe EPAR</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="laboratory">Section of Allergy and Immunology</orgName>
								<orgName type="institution">IPLESP</orgName>
								<address>
									<settlement>Paris</settlement>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Direcci on de Investigaci on e Innovaci on Sanitaria</orgName>
								<orgName type="department" key="dep2">Departamento de Salud</orgName>
								<orgName type="department" key="dep3">Department of Pe-diatrics</orgName>
								<orgName type="institution">Saint Louis University School of Medicine</orgName>
								<address>
									<addrLine>Gobierno Vasco-Eusko Jaurlaritza</addrLine>
									<settlement>Vitoria-Gasteiz</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department">Department of Otorhinolaryngology</orgName>
								<orgName type="institution">University of Antioquia</orgName>
								<address>
									<settlement>Medellin</settlement>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="institution">Academic Medical Centre</orgName>
								<address>
									<settlement>Amsterdam</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Mark</forename><surname>Dykewicz</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Itziar</forename><surname>Etxeandia-Ikobaltzeta</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MSc</roleName><forename type="first">Ivan</forename><forename type="middle">D</forename><surname>Florez</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Wytske</forename><surname>Fokkens</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joao</forename><surname>Fonseca</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Faculdade de Medicina</orgName>
								<orgName type="institution" key="instit1">CINTESIS-Center for Health Technology and Services Research</orgName>
								<orgName type="institution" key="instit2">Universidade do Porto &amp; Allergy</orgName>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department">Department of Otorhinolaryngology</orgName>
								<orgName type="institution">CUF Porto Hospital and Instituto</orgName>
								<address>
									<settlement>Porto</settlement>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Department of Otorhinolaryngology</orgName>
								<orgName type="department" key="dep2">Center of Rhinology and Allergology</orgName>
								<orgName type="department" key="dep3">Division of Internal Medicine Asthma and Allergy</orgName>
								<orgName type="department" key="dep4">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Uni-versity Hospitals Leuven</orgName>
								<orgName type="institution" key="instit2">Academic Medical Center (AMC)</orgName>
								<address>
									<addrLine>Wies-baden</addrLine>
									<settlement>Amsterdam</settlement>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">Institute of Family Medicine and Public Health</orgName>
								<orgName type="department" key="dep2">Department of Paediatrics</orgName>
								<orgName type="institution" key="instit1">Medical University of Lodz</orgName>
								<orgName type="institution" key="instit2">Uni-versity of Tartu; w Hospital M edica Sur</orgName>
								<address>
									<settlement>Mexico City</settlement>
								</address>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="department" key="dep3">Di-vision of Allergy &amp; Immunology</orgName>
								<orgName type="institution" key="instit1">Oslo University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Oslo</orgName>
								<orgName type="institution" key="instit3">Royal Col-lege of Surgeons in Ireland Medical School</orgName>
								<address>
									<settlement>Dublin</settlement>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>San Diego</settlement>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="institution">aa Unitat de Rinologia i Cl ınica de l&apos;Olfacte</orgName>
								<address>
									<addrLine>Servei d&apos;ORL</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">Department of Women</orgName>
								<orgName type="institution" key="instit1">Hospital Cl ınic, Clinical &amp; Experi-mental Respiratory Immunoallergy</orgName>
								<orgName type="institution" key="instit2">IDIBAPS</orgName>
								<address>
									<settlement>Barcelona</settlement>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="institution" key="instit1">Child Health &amp; Food Allergy Referral Centre Veneto Region</orgName>
								<orgName type="institution" key="instit2">University of Padua; cc Alfred Hospital and Monash University</orgName>
								<address>
									<settlement>Melbourne</settlement>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Department of Immu-nology and Allergology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine in Pilsen</orgName>
								<orgName type="institution">dd National Hospital Organization Tokyo National Hospital</orgName>
								<address>
									<addrLine>Kiyose-city</addrLine>
									<settlement>Tokyo</settlement>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Division of Infection, Immunity &amp; Respiratory Medicine</orgName>
								<orgName type="department" key="dep2">Depart-ment of Allergy and Rheumatology</orgName>
								<orgName type="institution" key="instit1">Charles University in Prague; ff the Allergy Department</orgName>
								<orgName type="institution" key="instit2">2nd Pediatric Clinic</orgName>
								<orgName type="institution" key="instit3">University of Athens</orgName>
								<orgName type="institution" key="instit4">University of Manchester</orgName>
								<orgName type="institution" key="instit5">Ajou University School of Medicine</orgName>
								<address>
									<settlement>Suwon</settlement>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Nippon Medical School</orgName>
								<orgName type="institution" key="instit1">ii Al-lergy and Respiratory Diseases</orgName>
								<orgName type="institution" key="instit2">IRCCS San Martino</orgName>
								<orgName type="institution" key="instit3">IST</orgName>
								<orgName type="institution" key="instit4">University of Genoa</orgName>
								<address>
									<settlement>Tokyo</settlement>
								</address>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Department of Family Medicine</orgName>
								<orgName type="laboratory">Al-lergy and Respiratory Research Group</orgName>
								<orgName type="institution" key="instit1">University of Aber-deen</orgName>
								<orgName type="institution" key="instit2">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Department of Prevention of Environmental Hazards and Allergology</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="department" key="dep3">Centre for Applied Research</orgName>
								<orgName type="laboratory">pp the Allergy Unit</orgName>
								<orgName type="institution" key="instit1">Usher Institute of Population Health Sciences and Informatics</orgName>
								<orgName type="institution" key="instit2">University of Edinburgh</orgName>
								<orgName type="institution" key="instit3">HIV/STI Surveillance Research Cen-ter, and World Health Organization Collaborating Center for HIV Surveillance</orgName>
								<orgName type="institution" key="instit4">Insti-tute for Futures Studies in Health</orgName>
								<orgName type="institution" key="instit5">Kerman University of Medical Sciences</orgName>
								<orgName type="institution" key="instit6">Medical Univer-sity of Warsaw</orgName>
								<orgName type="institution" key="instit7">University Hospital of Z€ urich and Christine K€ uhne Center for Allergy Research and Education CK-CARE</orgName>
								<address>
									<settlement>Davos; qq Asthma</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department">rr Asthma and Inflammation</orgName>
								<orgName type="institution" key="instit1">Usher Institute of Population Health Sciences and Informatics</orgName>
								<orgName type="institution" key="instit2">University of Edinburgh</orgName>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department" key="dep1">Department of Pneumology and Allergy</orgName>
								<orgName type="department" key="dep2">Immunoall ergia Respirat oria Cl ınica I Experimental (IDIBAPS)</orgName>
								<orgName type="laboratory">Centro de Investigaciones Biom edicas en Red de Enfermedades Respiratorias (CIBERES)</orgName>
								<orgName type="institution" key="instit1">National Institute of Allergy and Infectious Diseases</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<address>
									<addrLine>Be-thesda</addrLine>
									<settlement>Barcelona</settlement>
								</address>
							</affiliation>
							<affiliation key="aff36">
								<orgName type="institution">tt Vilnius University Clinic of Children&apos;s Diseases and Public Health Institute</orgName>
								<address>
									<settlement>Vilnius</settlement>
								</address>
							</affiliation>
							<affiliation key="aff37">
								<orgName type="department" key="dep1">EAP/UEMS-SP)</orgName>
								<orgName type="department" key="dep2">Department of Lung Diseases and Clinical Immunology</orgName>
								<orgName type="institution">European Academy of Paediatrics</orgName>
								<address>
									<settlement>Brussels</settlement>
								</address>
							</affiliation>
							<affiliation key="aff38">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University of Turku and Allergy Clinic Terveystalo Turku; vv Nova Southeastern University</orgName>
								<address>
									<settlement>Fort Lauderdale</settlement>
								</address>
							</affiliation>
							<affiliation key="aff39">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Sachs&apos; Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">South General Hospital and Institute of Environmental Medicine</orgName>
								<orgName type="institution" key="instit3">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
								</address>
							</affiliation>
							<affiliation key="aff40">
								<orgName type="department">Department of Otolaryngology Head and Neck Surgery</orgName>
								<orgName type="institution">University of Antioquia</orgName>
								<address>
									<addrLine>Medell ın</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff41">
								<orgName type="department" key="dep1">Department of Dermatology and Al-lergy</orgName>
								<orgName type="department" key="dep2">Division of General Internal Medicine</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="institution" key="instit1">Beijing TongRen Hospital</orgName>
								<orgName type="institution" key="instit2">Beijing Institute of Otolaryngology</orgName>
								<orgName type="institution" key="instit3">zz University Clinic of Pulmonary and Allergic Diseases Golnik</orgName>
								<address>
									<settlement>Charit e-Universit€ atsmedizin Berlin</settlement>
								</address>
							</affiliation>
							<affiliation key="aff42">
								<orgName type="institution">McMaster University</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><forename type="middle">W</forename><surname>Hellings</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Ludger</forename><surname>Klimek</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Sergio</forename><surname>Kowalski</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Piotr</forename><surname>Kuna</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Kaja-Triin</forename><surname>Laisaar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Ee</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><surname>Larenas-Linnemann</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Karin</forename><forename type="middle">C</forename><surname>Lødrup Carlsen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Manning</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eli</forename><surname>Meltzer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Joaquim</forename><surname>Mullol</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, aa</roleName><forename type="first">Antonella</forename><surname>Muraro</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, bb</roleName><forename type="first">Robyn</forename><surname>O'hehir</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, cc</roleName><forename type="first">Ken</forename><surname>Ohta</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, dd</roleName><forename type="first">Petr</forename><surname>Panzner</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, ee</roleName><forename type="first">Nikolaos</forename><surname>Papadopoulos</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, ff,gg</roleName><forename type="first">Hae-Sim</forename><surname>Park</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, hh</roleName><forename type="first">Gianni</forename><surname>Passalacqua</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Ruby</forename><surname>Pawankar</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, kk</roleName><forename type="first">David</forename><surname>Price</surname></persName>
						</author>
						<author>
							<persName><roleName>DC, MSc</roleName><forename type="first">John</forename><forename type="middle">J</forename><surname>Riva</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Yetiani</forename><surname>Rold An</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, mm</roleName><forename type="first">Dermot</forename><surname>Ryan</surname></persName>
						</author>
						<author>
							<persName><roleName>PharmD, MPH, nn</roleName><forename type="first">Behnam</forename><surname>Sadeghirad</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Boleslaw</forename><surname>Samolinski</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Peter</forename><surname>Schmid-Grendelmeier</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MSc, qq</roleName><forename type="first">Aziz</forename><surname>Sheikh</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, rr</roleName><forename type="first">Alkis</forename><surname>Togias</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Antonio</forename><surname>Valero</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, ss</roleName><forename type="first">Arunas</forename><surname>Valiulis</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, tt</roleName><forename type="first">Erkka</forename><surname>Valovirta</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, uu</roleName><forename type="first">Matthew</forename><surname>Ventresca</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, vv</roleName><forename type="first">Dana</forename><surname>Wallace</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Susan</forename><surname>Waserman</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">the Division of Clinical Immunology and Allergy</orgName>
								<orgName type="institution">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Magnus</forename><surname>Wickman</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Wojtek</forename><surname>Wiercioch</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MSc</roleName><forename type="first">Juan</forename><surname>Jos E Yepes-Nuñez</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Luo</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Yuan</forename><surname>Zhang</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MSc, zz</roleName><forename type="first">Mihaela</forename><surname>Zidarn</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, aaa</roleName><forename type="first">Torsten</forename><surname>Zuberbier</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Holger</forename><forename type="middle">J</forename><surname>Sch€ Unemann</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Jan</forename><forename type="middle">L</forename><surname>Bro_ Zek</surname></persName>
							<email>jan.l.brozek@gmail.com</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Ghent and Brussels</orgName>
								<orgName type="department" key="dep2">Sydney and Melbourne</orgName>
								<orgName type="institution">Hamilton and Toronto</orgName>
								<address>
									<settlement>Montpellier and Paris, Brasov, Padua, and Genoa</settlement>
									<region>Ontario, Milan</region>
									<country>Canada, France, Romania;, Belgium;, Australia, Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Fla; Leiden and Amsterdam</orgName>
								<orgName type="department" key="dep2">Braga/Guimarães and Porto</orgName>
								<orgName type="institution">Tampa and Fort Lauderdale</orgName>
								<address>
									<settlement>Salvador</settlement>
									<country>The Netherlands, Portugal, Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Vitoria-Gasteiz and Barcelona</orgName>
								<address>
									<settlement>St Louis, Mo, Medellin, Berlin, Lodz, Tartu, Mexico City, Mexico, Oslo, Dublin, San Diego, Calif, Tokyo, Prague</settlement>
									<country>Spain, Colombia; Wiesbaden, Germany, Poland, Estonia, Norway, Ireland, Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">and Golnik</orgName>
								<orgName type="institution">Czech Republic</orgName>
								<address>
									<addrLine>and Edinburgh, Md; Vilnius</addrLine>
									<settlement>Athens, Manchester, Aberdeen, Suwon, Kerman, Warsaw, Davos, Bethesda, Turku, Stockholm, Beijing</settlement>
									<country>Greece, United Kingdom, Korea, Iran, Poland, Switzerland, Lithuania, Finland, Sweden, China, Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Clinical Epidemiology and Biostatistics</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff43">
								<orgName type="department">Department of Clinical Epidemiology and Biostatistics</orgName>
								<orgName type="institution">McMaster University</orgName>
								<address>
									<postCode>L8S 4K1</postCode>
									<settlement>Hamilton</settlement>
									<region>Ontario</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-06-08">June 8, 2017.</date>
						</imprint>
					</monogr>
					<idno type="MD5">B084A601A5C8094B76596E7AE169A9BD</idno>
					<idno type="DOI">10.1016/j.jaci.2017.03.050</idno>
					<note type="submission">Received for publication October 3, 2016; revised February 12, 2017; accepted for publication March 15, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:19+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Allergic rhinitis (AR) affects 10% to 40% of the population.</s><s>It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice.</s><s>Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma.</s><s>New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update.</s><s>Objective: We sought to provide a targeted update of the ARIA guidelines.</s></p><p><s>Disclosure of potential conflict of interest: J. L. Bro_ zek has received support for the development of systematic reviews in these guidelines from the ARIA Initiative.</s><s>J. Bousquet has received personal fees from Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, Chiesi, GlaxoSmithKline, and Menarini.</s><s>S. Bosnic-Anticevich is on the advisory board for TEVA; has consultant arrangements with MEDA and GlaxoSmithKline; has received grants from TEVA; has received payment for lectures from TEVA, GlaxoSmithKline, and AstraZeneca; has received payment for manuscript preparation from MEDA; and has received payment for development of educational presentations from GlaxoSmithKline.</s><s>Allergic rhinitis (AR) is among the most common diseases globally and usually persists throughout life. <ref type="bibr" target="#b0">1</ref> The prevalence of self-reported AR has been estimated to be approximately 2% to 25% in children <ref type="bibr" target="#b1">2</ref> and 1% to greater than 40% in adults. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b2">3</ref></s><s>The prevalence of confirmed AR in adults in Europe ranged from 17% to 28.5%.</s><s>Recent studies show that the prevalence of AR has increased in particular in countries with initial low prevalence (for a discussion of prevalence of AR, see section 5.1-5.2 in Allergic Rhinitis and its Impact on Asthma [ARIA] 2008 Update <ref type="bibr" target="#b0">1</ref> ).</s><s>Classical symptoms of AR are nasal itching, sneezing, rhinorrhea, and nasal congestion.</s><s>Ocular symptoms are also frequent; allergic rhinoconjunctivitis is associated with itching and redness of the eyes and tearing.</s><s>Other symptoms include itching of the palate, postnasal drip, and cough.</s></p><p><s>7]<ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref> In addition, AR is a risk factor for asthma, <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b8">9</ref> and uncontrolled moderate-to-severe AR affects asthma control. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref></s><s>ompared with other medical conditions, AR might not appear to be serious because it is not associated with severe morbidity and mortality.</s><s>However, the burden and costs are substantial. <ref type="bibr" target="#b11">12</ref></s><s>R reduces the quality of life of many patients, impairing sleep quality and cognitive function and causing irritability and fatigue.</s><s>AR is associated with decreased school and work performance, especially during the peak pollen season. <ref type="bibr" target="#b0">1</ref> AR is a frequent reason for general practice office visits.</s><s>]<ref type="bibr" target="#b14">[15]</ref> Appropriate treatment of AR improves symptoms, quality of life, and work and school performance.</s></p><p><s>Clinical practice guidelines for AR management were developed over the past 20 years <ref type="bibr" target="#b15">16</ref> and have improved the care of patients with AR. <ref type="bibr" target="#b16">17</ref> However, transparent reporting of guidelines to facilitate understanding and acceptance are needed.</s><s>The ARIA initiative was initiated during a World Health Organization workshop in 1999 <ref type="bibr" target="#b17">18</ref> and updated in 2008. <ref type="bibr" target="#b0">1</ref> The ARIA 2010 revision was the first evidence-based guideline in allergy to follow the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach <ref type="bibr" target="#b18">19</ref> with no influence of for-profit organizations and an explicit declaration and management of potential competing interests of panel members. <ref type="bibr" target="#b19">20</ref></s><s>It summarized the potential benefits and harms underlying the recommendations, as well as assumptions around values and preferences that influenced the strength and direction of the recommendations.</s><s>In 2014, the ARIA revision was found to rank first in the rigor of development and quality of reporting of guidelines about the management of AR, <ref type="bibr" target="#b15">16</ref> although recent guidelines published later were not considered. <ref type="bibr" target="#b20">21</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLINICAL QUESTIONS</head><p><s>Since the last revision of the ARIA guidelines in 2010, <ref type="bibr" target="#b19">20</ref> new treatments have become available, and new evidence has accumulated about selected other treatments.</s><s>By using a modified Delphi process, the ARIA guideline panel selected new questions that required answering with recommendations or the existing recommendations that required an updated review of the evidence and potentially updating the recommendations themselves.</s><s>Therefore this revision of the ARIA guidelines is limited in scope and addresses 6 questions about the treatment of AR:</s></p><p><s>1. Should a combination of oral H 1 -antihistamine and intranasal corticosteroid versus intranasal corticosteroid alone be used for treatment of AR? 2. Should a combination of intranasal H 1 -antihistamine and intranasal corticosteroid versus intranasal corticosteroid alone be used for treatment of AR? 3. Should a combination of an intranasal H 1 -antihistamine and an intranasal corticosteroid versus intranasal H 1 -antihistamine alone be used for treatment of AR? 4. Should a leukotriene receptor antagonist versus an oral H 1antihistamine be used for treatment of AR? 5. Should an intranasal H 1 -antihistamine versus an intranasal corticosteroid be used for treatment of AR? 6.</s><s>Should an intranasal H 1 -antihistamine versus an oral H 1antihistamine be used for treatment of AR?</s></p><p><s>The target audience of these guidelines is primary care clinicians, school nurses, pharmacists, specialists in allergy and clinical immunology, general internists managing patients with AR, and pediatricians.</s><s>Ear-nose-throat specialists, other health</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations used</head><p><s>AR: Allergic rhinitis ARIA: Allergic Rhinitis and its Impact on Asthma EtD: Evidence to decision GRADE: Grades of Recommendation, Assessment, Development, and Evaluation ICP: Integrated care pathway PAR: Perennial allergic rhinitis SAR: Seasonal allergic rhinitis SMD: Standardized mean difference care professionals, and health care policy makers can also benefit from these guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLASSIFICATION OF AR</head><p><s>The classification of AR was revised by ARIA in 2001.</s><s>A major change was the introduction of the terms ''intermittent'' and ''persistent.'' <ref type="bibr" target="#b17">18</ref></s><s>Before then, AR was classified, based on the time and type of exposure and symptoms, into seasonal allergic rhinitis (SAR; most often caused by outdoor allergens, such as pollens or molds), perennial allergic rhinitis (PAR; most frequently, although not necessarily, caused by indoor allergens such as house dust mites, molds, cockroaches, and animal dander), and occupational allergic rhinitis. <ref type="bibr" target="#b21">22,</ref><ref type="bibr">23</ref></s><s>With very few exceptions, published studies refer to SAR and PAR and enroll patients based on the offending allergen (pollen, house dust mites, or both), and we retained the terms SAR and PAR to enable the interpretation of published evidence.</s></p><p><s>The recommendations in the ARIA 2016 update apply directly to patients with moderate-to-severe AR.</s><s>They might be less applicable to treatment of patients with mild AR who frequently do not seek medical help and manage their symptoms themselves with medications available other the counter.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RECOMMENDATIONS FOR CHILDREN</head><p><s>Almost all studies used to answer the questions in this update of the ARIA guidelines included exclusively adult patients.</s><s>However, careful extrapolation to the pediatric population can be attempted.</s><s>One can assume that the relative effects of treatment of AR are likely similar among adults and children, but adverse effects might be more or less frequent, and their perception and importance might be different (eg, bitter taste).</s><s>Values and preferences for specific outcomes and treatments can also vary between adults and children.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODOLOGY</head><p><s>The full description of methods used to develop recommendations in these guidelines is described in the Methods section of the full version of the guideline document (see Online Repository item E1 in this article's Online Repository at www.jacionline.</s><s>org).</s><s>Here we describe briefly the methodology to facilitate the interpretation of the guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Questions and outcomes of interest</head><p><s>The scope and questions for this update of the ARIA guidelines were identified by the ARIA guideline panel members.</s><s>The guideline panel deemed the following outcomes to be important to patients: nasal and ocular symptoms, quality of life, work/ school performance, and adverse effects.</s><s>As for the previous revision of the ARIA guidelines, we did not formally assess the relative importance of each outcome of interest (ie, which outcomes are more and which are less important) but rather adopted the rating agreed upon by the guideline panel according to the structured discussion. <ref type="bibr" target="#b23">24</ref></s><s>In general, combined nasal symptoms, ocular symptoms, quality of life, work/school performance, and serious adverse effects were considered critical to the decision, and individual symptoms, a composite outcome of any adverse effects and adverse effects that were not serious or did not lead to discontinuation of treatment, were considered important but not critical (see evidence profiles in Online Repository item E2 in this article's Online Repository at www.jacionline.</s><s>org).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evidence review and development of clinical recommendations</head><p><s>For each question, the methodology group performed a full systematic review of the literature to identify and summarize evidence about the effects of interventions on the outcomes of interest.</s><s>We also searched systematically for information about patients' values and preferences and resource use (cost).</s><s>We systematically searched the Medline, Embase, and Cochrane CENTRAL electronic databases.</s><s>Titles and abstracts and subsequently full-text articles were screened in duplicate to assess eligibility according to prespecified criteria.</s><s>Panel members were contacted to confirm completeness of the body of evidence and suggest additional articles that might have been missed in electronic searches.</s></p><p><s>To obtain the estimates of effects on each outcome of interest, we performed meta-analyses using the Cochrane Collaboration Review Manager Software, version 5.3.5. <ref type="bibr" target="#b24">25</ref> We prepared evidence summaries (see Online Repository item E2) for each question according to the GRADE approach <ref type="bibr" target="#b18">19</ref> by using the GRADEpro Guideline Development Tool online application (www.gradepro.org).</s></p><p><s>When continuous outcomes (eg, symptom scores or quality of life) are measured by using different scales, the results can only be combined in meta-analysis by using the standardized mean difference (SMD), which is expressed in SD units. <ref type="bibr" target="#b26">26</ref></s><s>Results expressed as an SMD are challenging to interpret.</s><s>To facilitate understanding, we used interpretation of the effect size according to Cohen conventional criteria <ref type="bibr" target="#b27">27</ref> : an SMD of around 0.2 is considered a small effect, an SMD of around 0.5 is considered a moderate effect, and an SMD of around 0.8 or higher is considered a large effect.</s><s>We used this interpretation throughout this document when we referred to effects of interventions as small, moderate, or large.</s></p><p><s>We assessed the risk of bias at the outcome level by using the Cochrane Collaboration's risk of bias tool. <ref type="bibr" target="#b28">28</ref></s><s>Subsequently, we assessed the certainty of the body of evidence (ie, confidence in the estimated effects, which is also known as ''quality of the evidence'') for each of the outcomes of interest according to the GRADE approach <ref type="bibr" target="#b29">29</ref> based on the following criteria: risk of bias, precision, consistency and magnitude of the estimates of effects, directness of the evidence, risk of publication bias, presence of a dose-effect relationship, and assessment of the effect of residual opposing confounding.</s><s>Certainty of the evidence was categorized into 4 levels: high, moderate, low, and very low.</s></p><p><s>For each question, we summarized all information in evidenceto-decision (EtD) frameworks (see Online Repository item E2) that included concise description of desirable and undesirable health effects, certainty of the evidence about those effects, evidence and assumptions about patients' values and preferences, required resources and cost-effectiveness, potential influence on health equity, acceptability of the intervention to various stakeholders, and feasibility of implementation. <ref type="bibr" target="#b30">30</ref></s><s>Judgments about all these factors and suggested recommendations in EtD frameworks were drafted by J.L.B., who was also a clinical expert.</s></p><p><s>EtDs for all questions were reviewed by the ARIA guideline panel members, who provided feedback by means of electronic communication and during a face-to-face meeting of Integrated Care Pathways for Airway Diseases (AIRWAYS ICPs) <ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> and Frailty European Innovation Partnership on Active and Healthy Ageing Reference Sites in Lisbon, Portugal on July 1, 2015. <ref type="bibr" target="#b33">33</ref></s><s>ll comments were addressed, and the frameworks were modified accordingly.</s><s>Modified EtD frameworks that included judgments about the research evidence, additional considerations of ARIA panel members, and draft recommendations were sent to all ARIA panel members for review and approval or disapproval and comments by using the online SurveyMonkey software (www.surveymonkey.com).</s><s>We recorded and addressed all agreements/disagreements, comments, and suggestions for changes.</s><s>We present the final EtD frameworks in Online Repository item E2.</s></p><p><s>Recommendations and their strength were decided by consensus.</s><s>The ARIA guideline panel agreed on the final wording of recommendations and remarks with further qualifications for each recommendation.</s><s>The final document, including the recommendations, was reviewed and approved by all members of the guideline panel.</s></p><p><s>According to the GRADE approach, the recommendations can be either ''strong'' or ''conditional'' depending on the guideline panel's confidence that following the recommendation would bring more good than harm to patients.</s><s>The wording of recommendations reflects their strength, and one can use the terms ''we recommend'' for strong recommendations and ''we suggest'' for conditional recommendations.</s><s>Box 1 provides suggested interpretation of strong and conditional recommendations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p><s>We present all recommendations in Table <ref type="table" target="#tab_1">I</ref>.</s><s>We provide the rationale for the recommendations and the consideration of all factors that influenced the recommendations: effects on all important health outcomes, certainty of the available evidence, values and preferences, acceptability by stakeholders, requirements for resources, feasibility, and any issues of health equity in the unabridged guideline document in Online Repository item E1.</s><s>Detailed summaries of the evidence supporting each recommendation and the guideline panel judgements are shown in Online Repository item E2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>How to use these guidelines</head><p><s>The ARIA guidelines about treatment of AR are not intended to impose a standard of care for individual countries.</s><s>They provide the basis for rational informed decisions for patients, parents, clinicians, and other health care professionals.</s><s>Clinicians, patients, third-party payers, institutional review committees, other stakeholders, or the courts should not view these recommendations as dictates.</s><s>Recommendations provide guidance for typical patients; no recommendation can take into account all of the often-compelling unique individual circumstances.</s><s>Thus, no one charged with evaluating health care professionals' actions should apply the recommendations from these guidelines by rote or in a blanket fashion.</s></p><p><s>Statements regarding the underlying values and preferences, as well as qualifying remarks accompanying each recommendation, should never be omitted when quoting or translating recommendations from these guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p><s>Evidence-based guidelines are at the cornerstone of integrated care pathways (ICPs), <ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32</ref> structured multidisciplinary care plans that promote translation of guideline recommendations into local protocols and their subsequent application in clinical practice.</s><s>Usually, several guidelines are available providing advice about the management of the same condition. <ref type="bibr" target="#b15">16</ref></s><s>It is important to wisely choose appropriate guidelines for local adaptation and creation of ICPs because most of them have limitations because of either the development of the guideline itself or the available research evidence and its interpretation.</s><s>The most common limitations of guidelines in AR are narrowness in scope (addressing only a small selection of important questions about the management of a given condition), suboptimal rigor of development and reporting, and inadequate representation of the views of patients and their caregivers. <ref type="bibr" target="#b15">16</ref></s><s>We acknowledge that for the ARIA 2016 update, we have not reviewed all recommendations from the ARIA 2010 guidelines.</s><s>However, we updated only 3 recommendations suggested by the ARIA panel members as requiring the update, and we addressed 3 new questions.</s><s>We also acknowledge that the ARIA guideline panel included allergists, ear-nose-throat specialists, pulmonologists, general practitioners, and pediatricians but did not include other health care professionals, pharmacists, and patients themselves.</s><s>However, for the ARIA 2016 update, we systematically searched and reviewed the published evidence about the patients' values and preferences regarding the outcomes and treatments for AR that to certain degree helped to overcome this limitation.</s><s>We summarized the results in the section about the assumed</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong recommendation</head><p><s>For patients: Most patients in this situation would want the recommended course of action, and only a small proportion would not.</s><s>For clinicians: Most patients should receive the intervention.</s><s>Adherence to a strong recommendation could be used as a quality criterion or performance indicator.</s><s>Formal decision aids are not likely to be needed to help patients make decisions consistent with their values and preferences.</s><s>For health care policy makers: The recommendation can be adopted as a policy or performance measure in most situations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conditional recommendation</head><p><s>For patients: The majority of patients in this situation would want the suggested course of action, but many would not.</s><s>For clinicians: Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences.</s><s>Decision aids might be useful in helping patients to make decisions consistent with their values and preferences.</s><s>For health care policy makers: Policy making will require substantial debate and involvement of various stakeholders.</s><s>Documentation of appropriate (eg, shared) decision-making processes can serve as a performance measure.</s><s>The available evidence has important limitations: (1) selective measurement and reporting of outcomes (eg, few studies properly measure and report quality of life, which is the most important outcome in patients with AR), (2) selection of patients for clinical trials that might not represent appropriately the patients seen in primary care, <ref type="bibr">34 and (3)</ref> not distinguishing between patients with different age or severity of symptoms (lack of proper stratification), <ref type="bibr" target="#b35">35</ref> thus limiting the applicability and generalizability of the research findings.</s><s>7]<ref type="bibr" target="#b38">[38]</ref> Such detailed, explicit, and transparent reporting of guidelines facilitates local adaptation of recommendations and their translation into ICPs.</s><s>Systematic and transparent summaries of the evidence clearly identifying gaps in available research evidence are needed to direct the research agenda and to avoid unnecessary expenditure of resources for further clinical research when it is not necessary. <ref type="bibr" target="#b39">39</ref></s><s>mplementation of guidelines in different settings and countries depends on the availability of health interventions (eg, medical tests, medications, and equipment), availability of resources, and cultural differences, among others.</s><s>Thus local adaptation of recommendations can be required, and ICPs need to be developed at the national, regional, or local level.</s><s>However, The panel members acknowledged that the choice of treatment will depend mostly on patient preferences and local availability and cost of treatment.</s></p><p><s>The panel members acknowledged that the choice of treatment will mostly depend on patient preferences and local availability and cost of treatment.</s></p><p><s>This is a conditional recommendation, and thus different choices will be appropriate for different patients.</s><s>Clinicians must help each patient to arrive at a decision consistent with her or his preferences, considering local availability, coverage, and costs.</s><s>This is a conditional recommendation, and thus different choices will be appropriate for different patients.</s><s>Clinicians must help each patient to arrive at a decision consistent with her or his preferences, considering local availability, coverage, and costs.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Box 1 .</head><label>1</label><figDesc><div><p><s>Strength of recommendation</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>T. Casale is the executive vice president of the American Academy of Allergy, Asthma &amp; Immunology.</s><s>J. Correia de Sousa has board memberships with Boehringer Ingelheim and Novartis, has received payment for lectures from Boehringer Ingelheim, and has received payment for development of educational presentations from Boehringer Ingelheim.</s><s>A. A. Cruz has board memberships with Novartis, Boehringer Ingelheim, AstraZeneca, MEDA Pharma, and GlaxoSmithKline; has consultant arrangements with Boehringer Ingelheim; has provided expert testimony for Boehringer Ingelheim; has received grants from GlaxoSmithKline; and has received payment for lectures from Eurofarma, Chiesi, MEDA Pharma, and Hypermarcas-Ache.</s><s>C. A. Cuello-Garcia has consultant arrangements with and has received payment for manuscript preparation and travel support from the World Allergy Organization.</s><s>P. Demoly has received consulting fees from ALK-Abell o, Stallergenes Greer, Thermo Fisher Scientific, MEDA, Chiesi, and Ysslab and has received grants from AstraZeneca.</s><s>M.</s></p></div></figDesc><table><row><cell>Methods: The ARIA guideline panel identified new clinical</cell></row><row><cell>questions and selected questions requiring an update. We</cell></row><row><cell>performed systematic reviews of health effects and the evidence</cell></row><row><cell>about patients' values and preferences and resource</cell></row><row><cell>requirements (up to June 2016). We followed the Grading of</cell></row><row><cell>Recommendations Assessment, Development, and Evaluation</cell></row><row><cell>(GRADE) evidence-to-decision frameworks to develop</cell></row><row><cell>recommendations.</cell></row><row><cell>Results: The 2016 revision of the ARIA guidelines provides both</cell></row><row><cell>updated and new recommendations about the pharmacologic</cell></row><row><cell>treatment of AR. Specifically, it addresses the relative merits of</cell></row><row><cell>using oral H 1 -antihistamines, intranasal H 1 -antihistamines,</cell></row><row><cell>intranasal corticosteroids, and leukotriene receptor antagonists</cell></row><row><cell>either alone or in combination. The ARIA guideline panel</cell></row><row><cell>provides specific recommendations for the choice of treatment</cell></row><row><cell>and the rationale for the choice and discusses specific</cell></row><row><cell>considerations that clinicians and patients might want to review</cell></row><row><cell>to choose the management most appropriate for an individual</cell></row><row><cell>patient.</cell></row><row><cell>Conclusions: Appropriate treatment of AR might improve</cell></row><row><cell>patients' quality of life and school and work productivity. ARIA</cell></row><row><cell>recommendations support patients, their caregivers, and health</cell></row><row><cell>care providers in choosing the optimal treatment. (J Allergy</cell></row><row><cell>Clin Immunol 2017;140:950-8.)</cell></row><row><cell>Key words: Allergic rhinitis, practice guideline</cell></row><row><cell>Larenas-Linnemann has consultant arrangements with MEDA, Boehringer Ingelheim,</cell></row><row><cell>and Mitfarma; has received grants from AstraZeneca, TEVA, Boehringer Ingelheim,</cell></row><row><cell>Novartis, GlaxoSmithKline, and MEDA; has received payment for lectures from</cell></row><row><cell>AstraZeneca, MEDA, Novartis, UCB, Boehringer Ingelheim, MSD, Pfizer, Grunen-</cell></row><row><cell>thal, Siegfried, and Armstrong; has received payment for development of educational</cell></row><row><cell>presentations from Grunenthal; and is on the safety board for DBV. K. C. Lodrup-</cell></row><row><cell>Carlsen has received travel support from the European Respiratory Society. E. Meltzer</cell></row><row><cell>has consultant arrangements with Allergan, AstraZeneca, Boehringer Ingelheim,</cell></row><row><cell>GlaxoSmithKline, Greer, Merck, Mylan, Regeneron-Sanofi, and Teva and has received</cell></row><row><cell>payment for lectures from GlaxoSmithKline, Greer, Merck, Mylan, and Teva. J. Mullol</cell></row><row><cell>has board memberships with Uriach, FAES, ALK-Abell o, Sanofi, Genentech, and</cell></row><row><cell>MEDA; has received grants from Meda, FAES, Uriach, GlaxoSmithKline, MSD; and</cell></row></table><note><p><s>Dykewicz has consultant arrangements with Alcon and Merck and is the Workgroup Char for the Rhinitis Practice Parameter Update of the American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma &amp; Immunology ACAAI Joint Task Force on Practice Parameters.</s><s>I. Etxeandia-Ikobaltzeta has received a consulting fee or honorarium from MacGRADE Centre.</s><s>W. Fokkens has consultant arrangements with MEDA/Mylan; has received grants from MEDA/Mylan, GlaxoSmithKline, MAPI S.A.S.-RWE, Allakos, and Sanofi; and has received payment for lectures from MEDA/Mylan.</s><s>J. Fonseca has received payment for lectures from A. Menarini and FAES Farma (Lab.</s><s>Vit oria) and has received payment for development of educational presentations and travel support from A. Menarini.</s><s>L. Klimek has board memberships with MEDA and Novartis; has consultant arrangments with ALK-Abell o, MEDA, Novartis, Allergopharma, Bionorica, Boehringer Ingelheim, GlaxoSmithKline, and Lofarma; has received grants from ALK-Abell o, Novartis, Allergopharma, Bionorica, GlaxoSmithKline, Lofarma, Biomay, HAL, LETI, Roxall, and Bencard; has received payment for lectures from ALK-Abell o, MEDA, Novartis, Allergopharma, Bionorica, Boehringer Ingelheim, GlaxoSmithKline, and Lofarma; has received payment for manuscript preparation from Bionorica; and has received payment for performing a clinical trial from ALK-Abell o. S. Kowalski is employed by Universidade Federal do Parana.</s><s>P. Kuna has board memberships with Boehringer Ingelheim, ALK-Abell o, FAES, Sandoz, Teva, Polpharma, Novartis, Allergopharma, and Celon Pharma; received payment for lectures from Adamed, Allergopharma, ALK-Abell o, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Faes, HAL Allergy, Lekam, Novartis, Polharma, Pfizer, Sandoz, and Teva; and has received travel support from Novartis, Berlin Chemie, and Boehringer Ingelheim.</s><s>D. E. has received payment for lectures from Uriach, Sanofi, MSD, Novartis, Menarini, MEDA, and UCB. A. Muraro has consultant arrangements with MEDA, Novartis, and Menarini; is employed by Padua University Hospital; and has received payment for lectures from MEDA and Menarini.</s><s>K. Ohta has received payment for lectures from Kyorin, AstraZeneca, Astellas, and Boehringer Ingelheim.</s><s>P. Panzner has board memberships with Allergy Therapeutics, Teva, and Novartis; has consultant arrangements with ALK-Abell o, ASIT Biotech, and AstraZeneca; and has received payment for lectures from Shire and Stallergenes.</s><s>N. Papadopoulos is on advisory boards for</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>Recommendations Question 1: Should a combination of an oral H1-antihistamine (OAH) and intranasal corticosteroid (INCS) vs INCS alone be used for treatment of AR? Recommendation 1A: In patients with SAR, we suggest either a combination of an INCS with an OAH or an INCS alone (conditional recommendation | low certainty of evidence).</s><s>Should a combination of an intranasal H 1 -antihistamine (INAH) and INCS vs an INCS alone be used for treatment of AR?</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell>Assumed values and preferences</cell><cell>Explanations and other considerations</cell></row><row><cell></cell><cell>ARIA guideline panel acknowledged that the</cell><cell>This is a conditional recommendation, and thus</cell></row><row><cell></cell><cell>choice of treatment would depend mostly on</cell><cell>different choices will be appropriate for</cell></row><row><cell></cell><cell>patient preferences and local availability and</cell><cell>different patients. In settings in which the</cell></row><row><cell></cell><cell>cost of treatment. Panel members assumed that</cell><cell>additional cost of an OAH is not large and/or</cell></row><row><cell></cell><cell>in the majority of situations, potential net</cell><cell>patients' values and preferences differ from</cell></row><row><cell></cell><cell>benefit would not justify spending additional</cell><cell>those assumed by guideline panel members, a</cell></row><row><cell></cell><cell>resources.</cell><cell>combination therapy might be a reasonable</cell></row><row><cell></cell><cell></cell><cell>choice, especially in patients whose symptoms</cell></row><row><cell></cell><cell></cell><cell>are not well controlled with an INCS alone,</cell></row><row><cell></cell><cell></cell><cell>those with pronounced ocular symptoms, or</cell></row><row><cell></cell><cell></cell><cell>those commencing treatment because of likely</cell></row><row><cell></cell><cell></cell><cell>faster onset of treatment effects.</cell></row><row><cell></cell><cell></cell><cell>This recommendation concerns regular use of</cell></row><row><cell></cell><cell></cell><cell>newer and less sedative OAHs and INCSs in</cell></row><row><cell></cell><cell></cell><cell>patients with SAR. For older OAHs with more</cell></row><row><cell></cell><cell></cell><cell>sedative effects, the balance of desirable and</cell></row><row><cell></cell><cell></cell><cell>undesirable effects may be different.</cell></row><row><cell>Recommendation 1B: In patients with PAR, we</cell><cell>-</cell><cell>Currently available evidence suggests that there is</cell></row><row><cell>suggest an INCS alone rather than a combi-</cell><cell></cell><cell>no additional benefit from a combination</cell></row><row><cell>nation of an INCS with an OAH (conditional</cell><cell></cell><cell>therapy compared with INCS alone, and there</cell></row><row><cell>recommendation | very low certainty of</cell><cell></cell><cell>might be additional undesirable effects. This</cell></row><row><cell>evidence).</cell><cell></cell><cell>recommendation is conditional because of</cell></row><row><cell></cell><cell></cell><cell>sparse information and thus very low certainty</cell></row><row><cell></cell><cell></cell><cell>of the estimated effects.</cell></row><row><cell>Question 2: Recommendation 2A: In patients with SAR, we</cell><cell>The panel members acknowledged that the choice</cell><cell>This is a conditional recommendation, and thus</cell></row><row><cell>suggest either a combination of an INCS with</cell><cell>of treatment will mostly depend on patient</cell><cell>different choices will be appropriate for</cell></row><row><cell>an INAH or an INCS alone (conditional</cell><cell>preferences and local availability and cost of</cell><cell>different patients. In settings in which the</cell></row><row><cell>recommendation | moderate certainty of ev-</cell><cell>treatment. At initiation of treatment</cell><cell>additional cost of combination therapy is not</cell></row><row><cell>idence).</cell><cell>(approximately the first 2 weeks), a</cell><cell>large and/or patients value potential benefits</cell></row><row><cell></cell><cell>combination of an INCS with an INAH might</cell><cell>more than any increased risk of adverse effects,</cell></row><row><cell></cell><cell>act faster than an INCS alone and thus might be</cell><cell>a combination therapy might be a reasonable</cell></row><row><cell></cell><cell>preferred by some patients.</cell><cell>choice.</cell></row><row><cell>Recommendation 2B: In patients with PAR, we</cell><cell>The panel members acknowledged that the choice</cell><cell>This is a conditional recommendation because of</cell></row><row><cell>suggest either a combination of an INCS with</cell><cell>of treatment will mostly depend on patient</cell><cell>the very low certainty of the evidence. At the</cell></row><row><cell>an INAH or an INCS alone (conditional</cell><cell>preferences and local availability and cost of</cell><cell>initiation of treatment (approximately the first</cell></row><row><cell>recommendation | very low certainty of</cell><cell>treatment.</cell><cell>2 weeks), combination of an INCS with an</cell></row><row><cell>evidence).</cell><cell></cell><cell>INAH might act faster than an INCS alone and</cell></row><row><cell></cell><cell></cell><cell>thus might be preferred by some patients.</cell></row><row><cell cols="3">Question 3: Should a combination of an INAH and INCS vs an INAH alone be used for treatment of AR?</cell></row><row><cell>Recommendation 3A: In patients with SAR, we</cell><cell>This recommendation places higher value on</cell><cell>This is a conditional recommendation, and thus</cell></row><row><cell>suggest a combination of an INCS with an</cell><cell>additional reduction of symptoms and improved</cell><cell>different choices will be appropriate for</cell></row><row><cell>INAH rather than an INAH alone (condi-</cell><cell>quality of life with a combination therapy</cell><cell>different patients. In settings in which the</cell></row><row><cell>tional recommendation | low certainty of</cell><cell>compared with an INAH alone. It places a lower</cell><cell>additional cost of a combination therapy is</cell></row><row><cell>evidence).</cell><cell>value on avoiding additional cost (expenditure</cell><cell>large, an alternative choice (ie, and INAH</cell></row><row><cell></cell><cell>of resources).</cell><cell>alone) might be equally reasonable. One panel</cell></row><row><cell cols="2">values and preferences in the full text of the ARIA 2016 update (see Online Repository item E1) and in the relevant sections of Question 4: Should a leukotriene receptor antagonist (LTRA) vs an OAH be used for treatment of AR? EtD tables (see Online Repository item E2).</cell><cell>member thought that the recommendation should be conditional for either the intervention or comparison.</cell></row><row><cell>Recommendation 4A: In patients with SAR, we</cell><cell>Panel members acknowledged that the choice of</cell><cell>Some patients with AR who have concomitant</cell></row><row><cell>suggest either an LTRA or an OAH (condi-</cell><cell>an LTRA or OAH will mostly depend on patient</cell><cell>asthma, especially exercise-induced and/or</cell></row><row><cell>tional recommendation | moderate certainty</cell><cell>preferences and local availability and cost of</cell><cell>aspirin-exacerbated respiratory disease, might</cell></row><row><cell>of evidence).</cell><cell>specific medications. In many settings an OAH</cell><cell>benefit from an LTRA more than from an OAH.</cell></row><row><cell></cell><cell>might still be more cost-effective, but this will</cell><cell>However, this recommendation applies to</cell></row><row><cell></cell><cell>largely depend on availability of generic LTRAs</cell><cell>treatment of AR but not to treatment of asthma.</cell></row><row><cell></cell><cell>and the local cost of various newer-generation</cell><cell>Patients with asthma who have concomitant AR</cell></row><row><cell></cell><cell>OAHs and LTRAs.</cell><cell>should receive an appropriate treatment according</cell></row><row><cell></cell><cell></cell><cell>to the guidelines for the treatment of asthma.</cell></row><row><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE I .</head><label>I</label><figDesc><div><p><s>(Continued)This is a conditional recommendation, and thus different choices will be appropriate for different patients based on their preferences for reduction of symptoms vs avoiding the risk of adverse effects.This might be more important for patients with PAR than those with SAR because they might use those medications for longer periods of time.Some patients with AR and concomitant asthma, especially exercise-induced and/or aspirinexacerbated respiratory disease, might benefit from an LTRA more than from an OAH.However, this recommendation applies to treatment of AR but not to treatment of asthma.Patients with asthma who have concomitant AR should receive an appropriate treatment according to the guidelines for the treatment of asthma.Question 5: Should an INAH vs an INCS be used for treatment of AR? Recommendation 5A: In patients with SAR, we suggest an INCS rather than an INAH (conditional recommendation | moderate certainty of evidence).</s><s>Recommendation 5B: In patients with PAR, we suggest an INCS rather than an INAH (conditional recommendation | low certainty of evidence).</s><s>This recommendation places a higher value on likely small but greater reduction of symptoms and improvement of quality of life with an INCS compared with an INAH and a lower value on avoiding larger cost of treatment with an INCS in many jurisdictions.</s><s>This recommendation places a higher value on probably greater reduction of nasal symptoms with an INCS compared with an INAH, although the overall difference is likely small.</s><s>It places a lower value on avoiding larger cost of treatment with an INCS in many jurisdictions.</s><s>This is a conditional recommendation, and thus different choices will be appropriate for different patients.</s><s>Clinicians must help each patient to arrive at a decision consistent with her or his values and preferences, considering local availability and costs.</s><s>This is a conditional recommendation, and thus different choices will be appropriate for different patients.</s><s>Clinicians must help each patient to arrive at a decision consistent with her or his values and preferences, considering local availability and costs.</s><s>Question 6: Should an INAH vs an OAH be used for treatment of AR? Recommendation 6A: In patients with SAR, we suggest either an INAH or OAH (conditional recommendation | low certainty of evidence).</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell>Assumed values and preferences</cell><cell>Explanations and other considerations</cell></row><row><cell>Recommendation 4B: In patients with PAR, we</cell><cell>This recommendation places a higher value on</cell><cell></cell></row><row><cell>suggest an OAH rather than a LTRA (condi-</cell><cell>possibly larger improvement of symptoms and</cell><cell></cell></row><row><cell>tional recommendation | low certainty of</cell><cell>quality of life with an OAH compared with an</cell><cell></cell></row><row><cell>evidence).</cell><cell>LTRA. It places a lower value on possible</cell><cell></cell></row><row><cell></cell><cell>increased risk of somnolence.</cell><cell></cell></row><row><cell>Recommendation 6B: In patients with PAR, we</cell><cell></cell><cell></cell></row><row><cell>suggest either an INAH or OAH (conditional</cell><cell></cell><cell></cell></row><row><cell>recommendation | very low certainty of</cell><cell></cell><cell></cell></row><row><cell>evidence).</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 4</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOLOCTOBER 2017</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">INAH, Intranasal H 1 -antihistamine; INCS, intranasal corticosteroid; LTRA, leukotriene receptor antagonist; OAH, oral H 1 -antihistamine. J ALLERGY CLIN IMMUNOL OCTOBER 2017</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Novartis, Faes Farma, BIOMAY, HAL, and Nutricia Research; has consultant arrangements with Menarini, ALK-Abell o, Novartis, MEDA, and Chiesi; has received grants from NESTEC and Menarini; and has received payment for lectures from Stallergenes, AbbVie, Novartis, MEDA, MSD, Omega Pharma, and Danone.</s><s>R. Pawankar is employed by Nippon Medical School and has received a grant from the Japanese Ministry of Education.</s><s>D. Price has board memberships with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva; has consultant arrangements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>they should always be based on systematically reviewed evidence of desirable and undesirable consequences.</s><s>The ARIA 2016 revision will be used to develop the ICPs proposed by the European Innovation Partnership on Active and Healthy Ageing <ref type="bibr" target="#b31">31,</ref><ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b40">40</ref> by using MASK (MACVIA-ARIA Sentinel Network).</s><s>ARIA is developing a novel implementation strategy using mobile technology <ref type="bibr" target="#b41">41,</ref><ref type="bibr" target="#b42">42</ref> and a clinical decision support system <ref type="bibr" target="#b41">41</ref> that is deployed in 21 countries. <ref type="bibr" target="#b43">43</ref></s><s>The ARIA 2016 revision will be embedded in the clinical decision support system for real-time patient stratification by using mobile technology.</s></p><p><s>Most of the recommendations are based on low-or very lowcertainty evidence, mainly because of the imprecision of the estimated effects due to few patients being studied.</s><s>For those questions, there is a need for more well-designed and executed randomized controlled trials that would measure and properly report all important outcomes.</s></p><p><s>Clinical implications: The 2016 revision of the ARIA guidelines offers updated advice for clinicians and patients about the most commonly used treatments for AR.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Khaltaev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Denburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Fokkens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Togias</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">86</biblScope>
			<biblScope unit="page" from="8" to="160" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Asher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Montefort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bjorksten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Strachan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Weiland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="733" to="743" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Katelaris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Potter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Maspero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cingi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopatin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="186" to="207" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey</title>
		<author>
			<persName><forename type="first">B</forename><surname>Leynaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Neukirch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Liard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Neukirch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="301" to="304" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Gergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Turkeltaub</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="579" to="588" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sibbald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="895" to="901" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Asthma and allergic rhinitis in the same patients</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Weeke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="25" to="29" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students</title>
		<author>
			<persName><forename type="first">W</forename><surname>Greisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Settipane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Settipane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Proc</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="185" to="188" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Rhinitis is an independent risk factor for developing cough apart from colds among adults</title>
		<author>
			<persName><forename type="first">S</forename><surname>Guerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sherrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baldacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carrozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pistelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Pede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="343" to="349" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Corren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Adinoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Buchmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Irvin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="250" to="256" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Taramarcaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Gibson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">D003570</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lotvall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Simoens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Subramanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Church</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1275" to="1279" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Finnish nationwide allergy programme at mid-term-change of direction producing results</title>
		<author>
			<persName><forename type="first">T</forename><surname>Haahtela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Valovirta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hannuksela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Von Hertzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jantunen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kauppi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Finnish Med J</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="2165" to="2172" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Burden of respiratory disease in Thailand: results from the APBORD observational study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Thanaviratananich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Ghoshal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Muttalif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pothirat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">e4090</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Burden of respiratory disease in Korea: an observational study on allergic rhinitis, asthma, COPD, and rhinosinusitis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Hong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy Asthma Immunol Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="527" to="534" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Methodological rigor and reporting of clinical practice guidelines in patients with allergic rhinitis: QuGAR study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Padjas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kehar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aleem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mejza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="777" to="783" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>e4</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Cauwenberge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bremard-Oury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mounedji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Stevens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="733" to="741" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Allergic rhinitis and its impact on asthma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Cauwenberge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Khaltaev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="S147" to="334" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</title>
		<author>
			<persName><forename type="first">G</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brozek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="383" to="394" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bro_ Zek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Baena-Cagnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Casale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="466" to="476" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Clinical practice guideline: allergic rhinitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Seidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gurgel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baroody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Bonner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="S1" to="43" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">7. Rhinitis and sinusitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Dykewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="S520" to="529" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cauwenberge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Passalacqua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Durham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="116" to="134" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 2. Framing the question and deciding on important outcomes</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="395" to="400" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">The Nordic Cochrane Centre. Review manager (RevMan)</title>
		<imprint/>
	</monogr>
	<note>Computer program</note>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Version 5.3.5. Copenhagen: The Cochrane Collaboration</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jpt</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<ptr target="http://www.cochrane-handbook.org/" />
		<editor>Higgins JPT, Green S</editor>
		<imprint>
			<date type="published" when="2008-09">September 2008</date>
		</imprint>
		<respStmt>
			<orgName>Cochrane Statistical Methods Group</orgName>
		</respStmt>
	</monogr>
	<note>The standardized mean difference</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">Statistical power analysis for the behavioral sciences</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1988">1988</date>
			<pubPlace>New York: Routledge</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gotzsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Juni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page">5928</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 3. Rating the quality of evidence</title>
		<author>
			<persName><forename type="first">H</forename><surname>Balshem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Helfand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brozek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="401" to="406" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Development of the GRADE Evidence to Decision (EtD) frameworks for tests in clinical practice and public health</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mustafa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Santesso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Alonso-Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guyatt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="89" to="98" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">AIR-WAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barbara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bateman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bewick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Chavannes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1028" to="1033" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Integrated care pathways for airway diseases (AIRWAYS-ICPs)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Addis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Adcock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Agache</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Agusti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alonso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="304" to="323" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Portugal at the cross road of international chronic respiratory programmes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pinto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Barbara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Da Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Miguel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Port Pneumol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="230" to="232" />
			<date type="published" when="2006">2006. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">How representative are clinical study patients with allergic rhinitis in primary care?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Amouyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Daures</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="920" to="926" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Unmet needs in severe chronic upper airway disease (SCUAD)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Casale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lockey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="428" to="433" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines</title>
		<author>
			<persName><forename type="first">P</forename><surname>Alonso-Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brignardello-Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page">2089</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction</title>
		<author>
			<persName><forename type="first">P</forename><surname>Alonso-Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brignardello-Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Davoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page">2016</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels</title>
		<author>
			<persName><forename type="first">I</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brignardello-Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wiercioch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carrasco-Labra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cuello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Akl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Implement Sci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">93</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Allergy Asthma Rep</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="261" to="268" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Crooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hellings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Bel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bewick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Allergy</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hellings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arnavielhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bedbrook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="367" to="374" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e2</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">MASK-rhinitis, a single tool for integrated care pathways in allergic rhinitis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bourret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mercier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Camuzat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bedbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Demoly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Hosp Health Serv</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="36" to="39" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASKrhinitis): the new generation guideline implementation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Samolinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bachert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1372" to="1392" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
